By Chris Wack
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk.
Shares of the Ann Arbor, Mich., company are up 120% in the past 12 months.
Nexletol and Nexlizet are indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy.
Nexlizet, alone or in combination with other LDL-C lowering therapies, will reduce LDL-C in adults with primary hyperlipidemia. Nexletol, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy isn't possible, will reduce LDL-C in adults with primary hyperlipidemia.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 02, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。